Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price ...
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.
Analysts Issue Forecasts for YMAB FY2024 Earnings
Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...
Promising Preclinical Results of Y-Mabs Therapeutics’ CD38 SADA Platform Justify Buy Rating
Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...
ETF Daily News5d
Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Brookline Capital Management
Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...